Michael Davidson Sells 183,332 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 183,332 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.71, for a total value of $6,180,121.72. Following the transaction, the chief executive officer directly owned 174,144 shares in the company, valued at $5,870,394.24. This trade represents a 51.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

NewAmsterdam Pharma Stock Up 3.4%

NASDAQ:NAMS opened at $35.46 on Friday. The firm’s fifty day simple moving average is $34.06 and its 200 day simple moving average is $32.95. The stock has a market cap of $4.08 billion, a P/E ratio of -20.50 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. On average, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on NAMS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Stifel Nicolaus increased their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Guggenheim boosted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Royal Bank Of Canada upped their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.55.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $140,000. Empowered Funds LLC bought a new position in NewAmsterdam Pharma in the 4th quarter worth about $85,000. XTX Topco Ltd grew its position in NewAmsterdam Pharma by 1,714.1% during the 4th quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock valued at $4,823,000 after purchasing an additional 129,913 shares during the last quarter. Virtus Investment Advisers LLC increased its stake in NewAmsterdam Pharma by 32.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock valued at $251,000 after purchasing an additional 1,731 shares in the last quarter. Finally, Twinbeech Capital LP bought a new stake in NewAmsterdam Pharma during the 4th quarter valued at about $961,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.